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INTRODUCTION
 INTRODUCTION
Preterm  labour  and  delivery  before  37  weeks  of  gestation  is  a 
principal  contributor  to  perinatal  mortality  and  morbidity.   Despite 
advances in perinatal medicine in recent decades the problems of preterm 
delivery continues to frustrate  satisfactory reproductive outcomes with little 
progress  having been made in identifying and reducing the frequency of 
preterm birth. 
However  a  real  reduction  in  preterm delivery  rates  will  only  take 
place  through  an  improved  understanding  of  the  physiology  of  labour, 
identification of patients at  risk, prediction and prevention of its occurrence, 
early detection of its onset and effective tocolysis. 
Rush et  al,  reported that  85% of neonatal  deaths not  due to lethal 
congenital malformations occur in infants with gestational age between 32 
and 37 weeks. While the survival rate has improved greatly over the last 
three decades the incidence of major handicaps remains unchanged at 6-7% 
of all preterm births. 
The social  and emotional  cost  of perinatal mortality and morbidity 
associated  with  preterm  birth  is  immeasurable.  Ideally  preterm  labour 
should be prevented. However pharmacological inhibition of preterm labour 
remains the most effective means to delay delivery and improve neonatal 
outcome until a more effective means of prevention is identified. Our study 
is  concerned with the role  of   the  calcium channel  blocker,nifedipine  in 
preterm labour as a tocolytic agent.
REVIEW OF 
LITERATURE
REVIEW OF LITERATURE
DEFINITION
Preterm labour is  defined as the onset  of regular,  painful,  frequent 
uterine contractions causing progressive effacement and dilatation of cervix 
occurring before 37 completed weeks of gestation from the first day of last 
menstrual  period  (Anderson  1977).An  infant  born  before  37  completed 
weeks should be called preterm (WHO 1969,ACOG 1995).
The lower limit which correlates with the fetal viability is less clearly 
defined. In United States it is 20 weeks (ACOG, 1995). Royal College of 
Obstetricians and Gynecologists (RCOG) Working  Party considered it as 
24 weeks. FIGO defined it as 22 weeks of above. In India, for legal purpose 
of  viability  it  is  defined as  any gestation  carried  beyond 28 weeks  (196 
days).
INCIDENCE 
The incidence of preterm delivery rates is  developed countries lies 
between 5% and 10%( Rush  et al1979, NewZealand Health Statistics report 
1978). The incidence in India being 10-14% (FOGSI). 
IMPACT OF PRETERM BIRTH
The most common maternal complication is postpartum endometritis 
which usually responds to antibiotics. Maternal mortality and morbidity as a 
consequence of preterm labour is rare (Fernando Arias ,3rd ed).
Risks of Preterm Infant
Aside  from  survival,  appreciable  physical  and  intellectual 
compromise afflicts preterm infants. 
• Birth asphyxia
• RDS (Respiratory Distress Syndrome)
• Apnoea of prematurity
• Jaundice  
• Hemorrhage 
• Sepsis 
• Shock 
• Hypothermia                            
• Metabolic problems (hypoglycemia) 
• Intraventricular hemorrhage(Germinal matrix hemorrhage ) 
• Neonatal  encephalopathy  (Cerebral  palsy  /periventricular 
leukomalacia )
• Necrotising enterocolitis 
• Patent ductus arteriosus 
• Retrolental fibroplasia
• Sensorineural deafness 
• Recurrent respiratory infections 
• Bronchopulmonary dysplasia
• Developmental delay
• Learning difficulties 
• Reduced growth potential
• Enforced separation of  baby and mother 
• Feeding difficulties
The cost of preterm birth can be measured in terms of mortalitiy and 
morbidity and in short term and long term financial costs which increase 
with lower gestational age.Levit and coworkers(1995)found that more than a 
third of the dollars expended for infant health care during the first year of 
life is spent on the 7% of neonates born who weigh less than 2500gm. The 
components of the costs are nursery, medical staff, stay in neonatal intensive 
care unit and treatment such as ventilation, artificial surfactant, recombinant 
erythropoietin and surgical procedures. The long term financial implications 
are unknown if the child is handicapped either physical or mental. 
ETIOLOGY
 Only when the factors causing prematurity are clearly understood any 
intelligent attempt at prevention can be made.
Nearly 50-60% preterm births occur following spontaneous labour, 
30%  is  due  to  preterm  rupture  of  membranes  and  rest  are  iatrogenic 
(Goldenberg RL 2002; Leitich H. 2005).
Meis and colleagues 1995b analysed the causes and found one third 
were indicated deliveries for maternal or fetal benefit.
One of the major reasons for increase in incidence of preterm birth is 
increase in multiple pregnancies (fertility drugs and artificial reproductive 
technology)  and  increased  surveillance  and  intervention  in  high  risk 
pregnancies (Ian Donald 6th ed). 
 Infections 
a) Uterine 
Bobitt and Ledger  first suggested that unrecognized chorioamnionitis 
may  be  causally  related  to  preterm  labour.  They  documented  positive 
cultures   via  transcervical  needle  aspiration  or  intrauterine  catheters.  As 
many as 50% of spontaneous preterm birth may be associated with infection 
(Klein LL, Gibbs RS 2005). The common pathway of intrauterine infection 
is the ascending route. 
Colonization of genital tract with group B streptococcus infection is 
associated with preterm labour (Bobitt et al, Lamont et al.,).
Colonization with Chlamydia trichomatis (Martin et al., Harrison et 
al.,) Mycoplasma hominis and Ureaplasma urealyticum (Klein et al., 2005) 
is associated with preterm labour .
Asymptomatic bacterial vaginosis and Trichomonas vaginalis confers 
a modest risk of spontaneous preterm labour . Bacterial vaginosis (Gravett et 
al ) has association with low birth weight. 
Edward et al., reported higher incidence of positive gonorrhea culture 
in preterm labour.
 
b) Extrauterine
Especially urinary tract infections. High prematurity rate is associated 
with asymptomatic bacteruria (Robertson et al).
Other are systemic illness like pneumonia, pyelonephritis. Periodontal 
disease is associated with preterm labour (Xiong X 2006) .
2. Placental 
• Abnormal placentation (Causing decreased uteroplacental blood flow)
• Anatomical abnormalities 
• Placental praevia
• Abruptio placenta 
3. Uterine
• Congenital  abnormalities  1-3% (particularly  septate  and  bicornuate 
uterus).
•  Incompetent Cervix and Cervical anatomical abnormalities 
• Overdistention of uterus 
4.Genetic (Genes  for  decidual  relaxin  /Fetal  mitochondrial  trifuntional 
protein defect, IL-1, β2 adrenergic receptor gene , tumor necrosis factor –α 
are implicated) 
5.Vaginal bleeding in early pregnancy is associated with preterm labour 
(Williams Obsterics, 22nded).  
6.Fetal 
Congenital anomalies 
7.Preterm labour of unknown origin( 20-30%)
 
PATHOPHYSIOLOGY
          The control of parturition is achieved by complex integration of 
endocrine, paracrine and autocrine mechanism. 
The fetal pituitary adrenal axis  needs to be intact (Gonik B et al). 
Stress induced release of corticotrophin releasing harmone (CRH) initiates 
parturition. 
When fetal  adrenal axis becomes more sensitive to ACTH there is 
increase in cortisol production, which leads to increased 17-hydroxylase and 
finally decreased progesterone.
 Differential  production of PGE2 and PGF2α  by the three enzymes- 
phospholipases,  PGH2 synthase,  15 hydroxy prostaglandin dehydrogenase 
may be key in the balance between uterine quiescence and activity. This 
decidual  activation and production of uterotropins is the penultimate event 
in initiation of labour .
Cox and colleges (1993) found that cytokines (1LI, 1L6, TNF , IL8) 
are  released  when  there  is  inflammatory  response  to  infection  and 
intrauterine  bleeding.  These  inturn  stimulate  arachidonic  acid  and 
prostaglandin production. 
EPIDEMIOLOGY
1. Race 
The incidence is greater among black women (Varner et al 2005).
2. Age
           It is more common in extremes of age.Lumley JM et al 1993, 
reported high incidence of preterm delivery in women under 17 years and 
over 35 years. 
3. Weight 
Poor  nutrition,  prepregnancy  weight  and  weight  gain  during 
pregnancy  play  a  important  role  in  causing  preterm  birth.  Hickly  and 
colleagues  1995,  have  shown  low  maternal  prenatal  gain  is  specifically 
associated with preterm birth. 
4. Stature 
Short statured mother have more tendency to produce smaller babies. 
5. Socio- Economic Status 
Women from lower socio economic status tends to be less educated 
and  would  not  have  satisfactory   general,  perinatal  and  antenatal  care 
(Goffinet F 2005).
6. Addictions 
Woman who smoke cigarettes or who abuse cocaine are at increased 
risk of preterm labour (Berns 2002).
7. Occupational Factors 
Those involved in manual work are more prone for preterm labour. 
PREDISPOSING FACTORS 
1.Stress
         Careers which involve considerable physical work and psychological 
stress are associated with increased preterm births (Papiernik & Kaninski 
1974).  Prolonged  standing  decreases  uteroplacental  blood  flow  and 
increases  the  frequency  of  large  placental  infarcts  causing  growth 
retardation. 
          Preterm birth is increased in women living alone, and those who are 
subjected to physical abuse. 
2.Coitus 
         Coitus was not found to be associated but increasing numbers of 
sexual partners increased the risk of recurrent preterm delivery (Yost NP et 
al 2006).
3.Reproductive History
a. Previous preterm birth 
            The history of one previous preterm birth is associated with a 
recurrence risk of 16-41% (Williams 22nd edition),  risk increasing with the 
number of preterm birth and decreasing with the number of term deliveries. 
b. Previous abortion
            There  is  increase  in  the  preterm deliveries  in  woman  who 
experienced one or more second trimester abortions. 
c. Cervical incompetence 
d. Uterine anomalies 
e. Pregnancy  Complications 
• Multiple pregnancies (Goldenberg RL, 2002)
• Hydramnios 
• Preclampsia
• Antepartum hemorrhage
• Second trimester bleeding  not due to placental causes 
4.Interpregnancy interval 
A significant increase in preterm birth was observed when the interval 
between birth and LMP of next pregnancy was less than 3 month. 
 5.Fetal Gender 
The main fetal factor influencing the rate of preterm delivery is fetal 
sex , with the  preponderance of males delivering preterm. 
PREDICTION OF PRETERM LABOUR
Risk scoring system 
A risk scoring system devised by Papiernik and modified by Creasy 
and Govik (1980) has been tested in several regions. Women with scores of 
more than 10 or more are considered to be at high risk for preterm labour.  
                                                                   
Scoring  systems  are  based  on  the  factors  which  increase  risk  of 
preterm  delivery,  the  risk  is  highest  with  a  previous  preterm  delivery. 
Bleeding in pregnancy, urinary tract  infections,  higher order pregnancies, 
body mass index <20kg /m2,  previous low birth weight babies and stress 
(family illness,  mortality, violence, financial) are associated with preterm 
delivery. Unfortunately risk scores don’t indentify the majority of women 
who deliver preterm. They are of limited clinical use (Honest H et al 2004) .
Cervical assessment 
Asymptomatic  cervical  dilatation  after  mid  pregnancy  has   gained 
attention as a risk factor for preterm delivery. 
Levino  and  associates  found  that  one  fourth  of  the  women  who 
cervices were dilated 2 to 3 cm between 26 and 30 weeks delivered before 
34 weeks.  Papiernik and Colleagues (1987) in, a study of cervical status 
before 37 weeks found that precocious cervical dilatation increased the risk 
of preterm labour. 
PAPIERNIK RISK SCORING SYSTEM
Points Socio-economic 
factors
Previous  medical 
history 
Daily habits Aspects of  current 
pregnancy 
1 Two  children  at 
home  ,Low  socio  – 
economic status 
Abortions - 1 Less 
than  1year(yr) 
since last birth 
Works outside Unusual fatigue 
2 Maternal  age  <20 
yrs or >40yrs ,single 
parent 
Abortions - 2 Smokes more than 
10  cigarettes  per 
day  more  than   3 
flights  of  stairs 
without elevator 
Gain  of  <5g  by  32 
weeks
3 Very  low  socio 
economic  status 
Heights <150 cm
Weight <45 kg
Abortions - 3 Heavy  or  stressful 
work  that  is  long 
and  tiring.  Long 
daily  commuting, 
extensive 
travelling 
Breech   32  weeks, 
weight  loss,  Head 
engaged  at  32 
weeks,   febrile 
illness.
4 Maternal  age  <18 
yrs 
Pyelonephritis Bleeding  after  12 
weeks, short cervix, 
opened  internal  os, 
uterine irritability
5 Uterine  anomaly, 
second  trimester 
abortion,  DES 
exposure 
,conebiopsy .
 Placentapraevia 
Hydramnios
6 Preterm  delivery, 
Repeated  second 
trimester abortion. 
Twins,  abdominal 
surgical procedure. 
Owen and  Colleagues  (2003)  concluded  that  the  value  of  cervical 
length to predict preterm birth before 35 weeks is apparent only in women at 
high risk for preterm birth.
Richly and Colleagues (1995) used transperineal sonography in 100 
women  with  complaints  consistent  with  imminent  preterm  birth  and 
compared sonographic measurement with those obtained with conventional 
cervical  examination.  This  has  the  advantage  of  avoiding  vaginal 
instrumentation with preterm ruptured membranes and placenta previa. 
   
         Ultrasound is a better modality than digital evaluation of cervical 
length because the upper half of by cervix which cannot be reached digitally 
can be measured by ultrasonogram. 
            Transvaginal ultrasound is better than transabdominal because of 
close proximity of cervix to probe and less distortion by transducer pressure 
or full bladder.
Fetal breathing movements
             Absence of fetal breathing movement on ultrasound performed at 
the time of admission on women who presented with threatened preterm 
labour was also found to be accurate test in predicting spontaneous preterm 
birth .
Uterine activity monitoring 
Current opinion is that for most patients home uterine monitoring is 
not better than frequent nursing contact and support .
          Katz and Associates found that women who has subsequent preterm 
delivery had increased uterine contractions at 30 weeks . 
        Only  patients,  who cannot  recognize adequately  the  presence  of 
contractions like multifetal  gestation and other overdistended uterus may 
benefit from home uterine monitoring . 
Fibronectins 
The presence of fetal fibronectin  in cervicovaginal secretions in late 
second and early third trimester has been proposed as a specific predictor of 
preterm labour (Lock wood and coworkers 1991).It represents disruption of 
choriodecidual interface  which can be caused by preterm labour. It can be 
measured  using  ELISA  and  values  exceeding  50ng/ml  are  considered 
positive result. However of concern is the high false positive rate if there is 
contamination with amniotic fluid, semen, maternal blood and in patients 
with cerclage. The test is more accurate in predicting spontaneous preterm 
birth  within  7-10  days  in  women  with  symptoms  of  threatened  preterm 
labour before advanced cervical dilatation. 
           The high negative predictive value of fetal fibronectin can be used to 
influence management (Honest H et al 2002).
            
  Honest  et  al  found that in  asymptomatic women ultrasonography 
measurement  of  cervical  length  using  cut  off  of  25mm or  less  between 
20-24 weeks  gestation  is  likely to  be accurate  in  predicting spontaneous 
preterm birth.  
         In  symptomatic  women the group found that cervicovaginal fetal 
fibronectin and absence of fetal breathing  movements on ultrasonogram are 
likely to be accurate in predicting preterm birth 
Biochemical markers
1. Salivary oestriol : progesterone ratio
2. Salivary oestriol   >1.8/ml before 34 weeks has a sensitivity of 68% 
and  specificity  of  76%  for  preterm  labour  before  35  weeks  of 
gestation (Darne et al )
3. Serum collagenase
4. Tissue  inhibitor  of  metalloproteinase  (TIMP)  /  Matrix 
Metalloproteinases 
5. Relaxin 
6. Corticotrophin Releasing Hormone (CRH)
7. Human chorionic gonadotropin 
8. Mediators of inflammation and infection 
a. C-Reactive protein
b. Granulocyte elastase
c. Cytokines (IL-6,TNF)
d. Amniotic fluid glucose concentration 
e. Zinc 
f. Lipocortin -1 (Romeo R et al)
g. Positive cultures 
h. Granulocyte colony stimulating factor 
These are not practically helpful in prediction of preterm labour 
DIAGNOSIS OF PRETERM LABOUR         
Symptoms of preterm labour 
 Menstrual like cramps 
 Low, dull back ache 
 Pressure (Feels like baby is pushing down)
 Abdominal cramping 
 Increase or change in vaginal  discharge 
 Uterine contractions that are 10 minutes apart or closer 
Cunningham  GH and coworkers (2001) found that preterm labour is 
considered to be established if regular uterine  contractions can be documented 
at least 4 in 20 minutes or 8 in 60 minutes with progressive change in cervical 
score with effacement 80% or more and dilatation more than 1cm. Contraction 
are 5 to 8 minutes apart.
If there is absence of cervical change in the presence of contractions the 
condition is Threatened Preterm Labour .
2) Pelvic examination
3) Ultrasongogram 
Ultrasonographic assessment in preterm labour
 Fetal viability
 Gestational age 
 Estimated fetal weight 
 Indicators of preterm labour
• Transvaginal cervical assessment 
• Fetal breathing movements 
 Amniotic fluid volume
 Number of fetus
 Fetal presentation and lie
 Fetal movements and tone
 Fetal anomaly 
 Placental localisation and morphology 
 Uterine fibroid and adnexal mass 
4.Tococardiography 
The amplitude, duration, shapes of contraction frequency and basal 
tone and monitored. The uterine activity is monitored .
Changes  in  FHR(Fetal  Heart  Rate)  pattern  occurring  in  preterm 
labour is normally due to immaturity of cardiovascular system. Repetitive 
late decelerations, absent variability and variable decelerations are sign of 
placental insufficiency. 
PREVENTION OF PRETERM LABOUR
I Basic care 
1. Support system of family and friends should be developed. 
2. Numerous suggestions on coping with physical and mental stresses 
of maintaining a pregnancy should be described. 
3. Education,  supportive  services  from  health  care  providers  and 
financial issues are of common concern. 
4.  Behavioural and lifestyle  modification 
a. Smoking cessation (Burguet et al )
b. Avoidance of illicit drugs 
c. Adequate nutrition. 
II Bedrest and Hydration 
Although bedrest and hydration are widely used as the first step of 
prevention and treatment, there is no evidence that this practice is beneficial 
(Freda MC et al, Goldenberg RL et al.,).
Bed rest should be advised with caution after evaluating its benefits 
and risks in an individual,  and not routinely keeping in mind its adverse 
effects like venous thrombosis and pulmonary edema. 
Aggressive treatment of cervicovaginal infection 
Bacterial vaginosis has been consistently associated with a 1.5 to 3 
times  increased  risk  of  spontaneous  preterm birth.   But  the  efficacy  of 
treatment in reduction of preterm births is conflicting (Goldenberg R, et al) 
1998).  But recent systematic review by Varma R, Gupta JK 2006 concluded 
that  screening  and  treatment  of  asymptomatic  bacteruria  and  bacterial 
vaginosis  in  low risk  population  groups  may  reduce  the  rate  of  preterm 
deliveries.
Most  Randomised control trials show that intravaginal  clindamycin 
cream  used  to  treat  bacterial  vaginosis  does  not  prevent  preterm  birth. 
(Kekki et al, 2001).
A  Cochrane  metaanalysis  by  King  &  Flenady  (2003)  of  10 
randomized  control  trials  found  no  difference  in  the  rates  of  newborn 
respiratory  distress  syndrome  or  of  sepsis  between  placebo  and 
antimicrobial treated group, but did find an increase in perinatal morbidity 
in  the  antimicrobial  treated  group.    Presence  of  GBS  (Group  B 
Streptococcus) colonisation in pregnancy has not been found to increase the 
rate of preterm delivery (Daskalakis G et al 2006).
Cervical Encerclage
A short cervix diagnosed by ultrasound in asymptomatic women may 
be an indication for cerclage. The role of cervical cerclage for the prevention 
of preterm delivery is now disputed. A number of systematic reviews which 
demonstrate a trend towards reduction in preterm deliveres before 34 weeks 
in  high  risk  women  who  had  cerclage  compared  to  those  managed 
expectantly (Honest H, et al).
Two randomized trials by Lazar et al., and Rush et al., did not show 
benefit for routine cerclage in women at moderate risk of preterm labour. 
Also cerclage has an inherent risk which actually increase preterm labour by 
increasing  the  pericervical  inflammation  or  infection.  Hence  unless  the 
diagnosis is specific it is not recommended.
But  a  MRC/  RCOG  trial  in  low  risk  women  demonstrated  that 
cerclage was associated with low risk of delivery below 33 wks.  
Progesterone 
Weekly  intramuscular  administration  to  women  at  high  risk  for 
preterm  labour  resulted  in  lower  rates  of  preterm  birth  and  perinatal 
mortality  when  compared  with  that  of  placebo,  Meis  and  collaboraters 
(2003).The dose used by Meis et al was 250 mg of 17 hydroxy progesterone 
caproate, intramuscularly every week from 20 to 36 weeks. 
In addition, da Fonseca and Colleges 2003 reported  the effectiveness 
of a 100mg vaginal suppository of natural progesterone to reduce preterm 
delivery in high risk women. 
A Cochrane Systematic Review in 2006 by Dodd JM et al found that 
the use of progesterone in women with history of spontaneous preterm birth 
resulted in a reduction in risk of preterm birth before 34 weeks of gestation 
and  Infant  birth  weight  less  than  2500  grams.  But  the  dose,  route  of 
administration and time for commencement of therapy has not been arrived 
conclusively by the study for need of further information. For women with 
threatened preterm labour the role of progesterone is uncertain as per this 
review. 
MANAGEMENT OF PRETERM LABOUR
Bedrest and hydration                
Steroids
             In 1995, a National Institute of Health Consensus Development 
Panel  recommended  corticosteroids  for  fetal  lung  maturation  in  preterm 
labour.Since  then  there  has  been  nearly  universal  acceptance  and 
implementation of these recommendations.
             All pregnant women between 24 and 34 weeks of gestation who are 
at risk of preterm delivery within 7 days should be considered candidates for 
antenatal corticosteroids.
           Recommended regimens includes a single course of two doses of 
12 mg of betamethasone given intramuscularly 24 hours apart,or four doses 
of 6mg of dexamethasone given intramuscularly 12 hours apart.
           A Cochrane Systematic Review by Rober D, Dalziel SR 2006 found 
that  antenatal  corticosteroids  reduce  neonatal  death,  respiratory  distress 
syndrome, intraventricular hemorrhage. Also antenatal corticosteroid is not 
associated with changes in the rates of maternal death, maternal infection, 
fetal  death,  neonatal  chronic  lung  disease  or  birth  weight.  It  is  also 
associated  with  a  reduction  in  incidence  of  necrotising  enterocolitis  and 
systemic infections in the first 48 hours of life as well as reduction in the 
need for respiratory support or neonatal intensive care unit admission.
            Although benefit on neonatal outcome is maximum between 24 
hours  and  7  days  after  initiation  of  therapy,  steroids  confer  significant 
survival advantages even when delivery occurs within 24 hours .Therefore 
treatment should not be withheld when delivery is probable within 24 hours.
Tocolysis
Tocolysis is pharmacological suppression of uterine activity. 
Indication:
Preterm  delivery  is  a  major  cause  of  perinatal  morbidity  and 
mortality.Tocolytic  agents  are  effective  in  reducing  the  likelihood  of 
delivery  within  48  hours  but  do  not  reduce  the  overall  risk  of  preterm 
delivery. 
Consideration should be given for administration of tocolytics to all 
women experiencing preterm labour when there is a delay in delivery
 -  to permit in-utero transfer to a tertiary perinatal centre for multi 
disciplinary management (obstetrician, neonatologist, anaesthetist); and /or
         -  to  gain  upto  48  hours  to  allow  for  the  administration  of 
corticosteroids to enhance pulmonary maturity.
BETA SYMPATHOMIMETICS 
Caritis  et  al  1976,  noted  that  small  doses  of  epinephrine  inhibited 
uterine  hyperactivity.  Efforts  to  produce  an  epinephrine  like  compound 
which lacked the cardiovascular stimulant effect culminated in the synthesis 
of  β agonists. 
I generation: - Isoxsuprine, Orciprenaline, isoprenaline 
II generation: - Ritodrine, Terbutaline, Fenoterol 
The  most  commonly  used  β2 agonist  for  tocolysis  is  ritodrine;  then  are 
terbutaline and salbutamol.
Ritodrine :- 
Ritodrine infusion is started at a dose of 50μg /min and increased very 
20 minutes until uterus is quiescent or side effects limit escalation of dose. 
Side  effects  are  palpitations,  tremor,  nausea,  headache,  chest  pain, 
dyspnoea,  pulmonary  edema,  hypokalemia,  myocardial  ischaemia, 
arrhythmias.
Terbulaline:-
Not  used  as  much  as  ritodrine,  but  is  effective  in  temporarily 
suppressing contraction when given parenterally.
   Intravenous dose is  5-10μg /min,  increased every 10-15 min  to a 
maximum of 80  μg. 2.5 -5mg  is given orally every 4-6 hours & 250μg 
subcutaneously  every 20-30 min ,given as 4-6 doses. Terbutaline has higher 
a risk of hyperglycemia than ritodrine. Other side effects are similar. But β2 
agonists are no longer the first choice of drugs for tocolysis because of their 
side effects  (RCOG Clinical  Guide lines,2002 and  Anotayanonth et  al., 
2004).
Contraindications of β2 agonist:-
• Symptomatic  cardiac  disease  especially  ventricular  outflow 
obstruction.
• Conduction disturbance. 
• Hyperthyroidism. 
• Sickle cell disease.
• Uncontrolled maternal diabetes mellitus.
• Chorioamnionitis. 
• Eclampsia or severe preeclampsia.
• Multifetal gestation.
• Severe obstetrical bleeding 
 
MAGNESIUM SULPHATE
MgSO4 uncouples the depolarisation contraction coupling. During the 
depolarisation of myometrial cells, Mg++ competes with Ca+ for entry into 
the  cell  causing  less  intracellular  Ca2+ to  participate  in  actin-myosin 
interaction during smooth muscle contraction.  It affects neural transmission 
by modifying acetyl choline release and sensitivity at motor end plate.
Contractility is inhibited at serum level of 5-8mEq/dl.  Deep tendon 
reflexes are lost at 9-13mEq/dl.  Respiratory depression occurs at > 14mEq/
dl.
Dosage
Intravenous  loading  dose  of  4g  administered  over  20  minutes 
followed by maintenance dose of 1-2g/hr.
Side  effects  include  flushing,  dizziness,  nausea,  lethargy,  chest 
tightness,  hypocalcemia,  pulmonary  edema,  respiratory  depression  and 
depressed  motor,  respiratory  activity  in  fetus.   It  is  contraindicated  in 
myasthenia gravis, heart block, renal disease, recent myocardial infarction.
Magnesium sulphate is an ineffective tocolytic agent as shown by a 
Cochrane systematic review( Crowther et al, 2002; Cox etal 1990).
PROSTAGLANDIN SYNTHETASE INHIBITORS
Drugs like aspirin, indomethacin,  naproxen fenamate  and sulindac 
inhibit the prostaglandin  synthesis , decrease the myometrial gap junctions 
and decrease the influx of calcium.
Maternal side effects includes nausea, vomiting, drug rash, headache, 
gastritis,  diarrhoea.  In  fetus  it  produces  constriction of  ductus arteriosus, 
pulmonary hypertension and oligohydramnios. Intraventricular hemorrhage, 
necrotising enterocolitis have also been reported.
They are effective as single dose in inhibiting the myometrial activity 
in many women at term (Reiss et al, 1997). Two randomised trials which 
compared  the  effect  of  indomethacin  and  placebo  in  delaying  delivery 
showed significant delay at 48 hours and at 7-10 days.
Comparison  with  agonists  show similar  efficacy,  but  a  better  side 
effect profile (RCOG guideline 2002). However,their use is limited because 
of their effects on the fetus. 
CALCIUM CHANNEL BLOCKERS
They are heterogenous group of organic compounds that inhibit the 
influx  of  extracellular  calcium across  the  cell  membrane  during  inward 
calcium current of action potential.They block the voltage sensitive L Type 
of calcium channels.  They also inhibit the release of intracellular calcium 
from the  sarcoplasmic  reticulum.   Thus  they  reduce  the  tone  of  smooth 
muscles.
The  commonly  used  drug  Nifedipine  is  a  potent  inhibitor  of 
myometrial contractions in non pregnant, pregnant and post partum uterus 
(Anderson et al, 1979).
Treatment Regime
The optimal dosing regime of Nifedipine has not yet defined.  Read 
and Wellby 1986, George et al 1991, showed that an initial dose of 30mg 
followed by 20mg 8th hourly for 3 days, reported a 75% successful tocolysis 
in 71% and 76% respectively. The tocolytic regimen given in Obstetrics and 
Gynaecology Clinics of North America ( Andrienne Z et al) is loading dose 
30 mg orally and maintenance dose of 10-20 mg orally every 4-6 hrs.
 
           In Clinical Obstetrics and Gynaecology 2000, Amy E et al found the 
following dosing regimens in various study protocols. Most administered a 
initial loading dose of 30mg of oral nifedipine followed by 10mg to 20mg 
dose every 4 to 6 hrs .Sublingual nifedipine loading doses are no longer 
advised.
Onset of action after oral nifedipine is less than 20 minutes with peak 
plasma concentration in 1 hour (range 15-90 min) and half life of 1.5 to 3 
hrs.  Duration of  action of  a single  dose can be as  long as  6 hrs  but  no 
apparent cumulative effect occurs when administered orally every 6 hour. 
Elimination is mainly through kidneys (70%) and bowels 30% (Amy et al).
Nifedipine has been compared to beta agonists in several randomised 
studies  which  suggest  that  calcium channel  blockers  are  more  effective, 
better tolerated with fewer side effects and have lower neonatal morbidity.
Side effects  include  facial  flushing,  nausea,  headache,  hypotension 
and tachycardia.  There is no significant alteration in serum electrolytes and 
blood glucose.
Mari et al, (1989) found that short term nifedipine does not adversely 
affect  uteroplacental  and fetal  blood flow when evaluated  by  doppler  at 
doses used for preterm labour.
OXYTOCIN ANTAGONISTS (ATOSIBAN)
There will  be increase in myometrial  oxytocin receptors  in labour. 
The  analogue  competitively  blocks  the  oxytocin  receptors  and  inhibits 
preterm labour.
Atosiban  is  given  intravenously  6.75mg  bolus  over  one  minute 
followed by infusion at 18mg/hr for 3 hours and then  6mg/hr for upto 45 
hours.  Duration of treatment should not exceed 48 hrs and the total dose 
should not exceed 330mg of atosiban.  Side effects are nausea, chest pain, 
vomiting and dyspnoea. Compared to β agonist atosiban has similar efficacy 
but a better side effect profile.
Royal College of Obstetricians and Gynaecologists guidelines 2002, 
suggest  that  if  tocolytics  are  administered,  the  first  choice  should  be 
oxytocin antagonists or Nifedipine. 
But compared with other tocolytics atosiban therapy is costly.
NITRIC OXIDE DONORS (GLYCERYL TRINITRATE)
Nitiric oxide is a potent endogenous hormone causing smooth muscle 
relaxation. 
The  NO donors  inhibit  corticotrophin  releasing  hormone  secretion 
which acts as a promoter of parturition. 
 10mg of Glyceryl Trinitrate  patch is  applied over the fundal region 
of  maternal  abdomen.  If  tocolysis   is  not  achieved in  one hour,  another 
10mg  patch  can  be  applied  to  a  maximum  dose  of  20mg  in  24  hours 
.Cochrane review (2000)by Duckitt K et al  showed that nitroglycerine did 
not  delay  delivery  or  improve  neonatal  outcome  when  compared  with 
placebo, no treatment or alternative tocolytics.
K+ CHANNEL OPENERS:
Diazoxide is a medication structurally related to the thiazide diuretics 
that is used in treatment of hypertensive crisis.  It inhibits contractility of 
smooth muscles, there by rendering myometrial quiescence. 
Dosage is 5mg /kg, given intravenously slowly in 15-30 minutes. The 
drug is  diluted in  half  normal  saline.  It  can also  be given in  boluses  of 
50-100mg every 5 minutes. 
Side  effects  are  hypotension,  tachycardia,  hyperglycemia,  and 
decreased uteroplacental blood flow secondary to maternal hypotension. The 
fetal side effects are hypoglycemia and fetal distress secondary to maternal 
hypotension. Further evaluation of this newer group of tocolytic drugs is 
needed. 
AIM OF THE 
STUDY
AIMS OF THE STUDY 
1. To study the efficacy of Nifedipine in prolonging the pregnancy in 
preterm labour. 
2. To record the effects of Nifedipine in the mother and the fetus. 
MATERIALS AND 
METHODS
MATERIALS AND METHODS
Study design
It is a prospective study conducted in Government RSRM Lying in 
Hospital attached to Stanley Medical College, Royapuram from September 
2008 to September 2009. The study population comprised of patients who 
attended either the hospital outpatient department or causality. There were 
100 patients in Nifedipine group and 10 patients were lost to follow up. 100 
cases were taken as controls of whom 13 cases were lost to follow up. Study 
group received nifedipine and control group were observed with bed rest. 
Both  the  groups  received  intramuscular  corticosteroids.  In  view  of  the 
ethical issue, written informed consent was obtained. 
Inclusion criteria
1. Gestational  age  (GA)between  28  to  34  weesks  as  determined  by 
menstrual dates, clinical examination, Ultrasonogram (USG) Abdomen
2. Uterine contractions. 4 contractions in 20 minute period lasting for 40 
-45 seconds 
3. Progressive cervical effacement upto 75%
4. Cervical dilatation upto 3 cm 
5. Intact membranes
Exclusion criteria 
Maternal conditions 
1. Rupture of Membranes
2. Infection 
3. Cervical dilatation greater than 3 cm
4. Antepartum hemorrhage 
5. Polyhydramnios/Oligohydramnios
6. Pregnancy induced hypertension(PIH)
7. Chronic hypertension 
8. Cardiac disease
9. Previous caesarean section 
10.Renal disease
11.Pulmonary disorder –Asthmatics, ARDS (Adult Respiratory Distress 
Syndrome)
12.Uncontrolled maternal diabetes mellitus.
Fetal factors 
1. Multiple gestation 
2. Fetal death / distress
3. IUGR(Intrauterine Growth Restriction)
4. Congenital anomalies
5. Erythroblastosis fetalis
Investigations 
1. Urine analysis 
2. Complete blood count 
3. Vaginal swab
4. ECG (Electrocardiogram)
5. USG Abdomen
Drug protocol 
On admission, patients were put in left lateral position. BP (Blood Pressure), 
PR (pulse rate) recorded. Cardiovascular System (CVS), Respiratory System 
(RS) examined. Steroids given. 
Group A 
             Cap. Nifedipine 10mg was given orally. If uterine contractions 
persisted after 20 minutes, the dose was repeated every 20 minutes, upto a 
maximum  total  dose  of  30mg  during  first  hour  of  treatment.  If  oral 
nifedipine  suppressed uterine activity, then maintenance therapy of 10mg 
6th hourly of oral nifedipine initiated 3 hrs after the last oral dose. This was 
continued for 3 days. 
           If uterine contractions did not cease within 1 ½ hours, patient was 
deemed a failure and treatment stopped. Treatment considered successful if 
there  was  abolition  of  uterine  contractions  and  no  progress  of  cervical 
dilatation and postponement of labour for atleast 48 hours. 
Group B
Observed with bed rest. 
Both the groups receive intramuscular corticosteroids. 
The variables monitored 
1. BP ,PR,Temperature,RR hourly during both phases.
2. Systolic BP<100mm Hg or PR >100 or Temperature >37.5 C will be 
reported.
3. Careful watch for side effects.
4. If initial cardiotocograph is reactive, FHR ( fetal heart rate) will be 
recorded hourly during stabilization phases and thereafter four hourly 
for first 48 hours. 
Definition of success (S)
Several  factors  have  been  considered  for  assessing  the  success  of 
tocolysis by various authors.
In this study successful tocolysis was defined as the delay of delivery 
with suppression of contractions for more than 48 hours form the initiation 
of therapy.  
Definition of Failure (F)
           The therapy was said to have failed  when the patient delivered 
within 48 hours of initiation of therapy, and tocolysis was stopped when 
cervical  dilation  progressed  to  >3cms  or  when  the  membranes  ruptured 
spontaneously. 
Hence this study confines itself to the study of idiopathic spontaneous 
preterm labour, comparing the efficacy of nifedipine with that of control in 
prolonging pregnancy for atleast 48 hours and studying the maternal  and 
fetal effects. 
RESULTS AND 
OBSERVATION
AGE  DISTRIBUTION
Table :1
                                   
                Maximum incidence of preterm delivery was observed in the 
20-29 years against the usual consensus that highest  incidence occurs in 
<19  and  >30years.  This  may  be  due  to  increased  age  at  marriage  and 
increased awareness of pregnancy complications in that age group.     
                     
Age in years
Nifedipine 
Group Control Group
No. % No. %
<19 10 8.89% 6 6.80%
20-29 44 84.44% 77 88.5%
>30 36 6.67% 4 4.5%


SOCIO ECONOMIC STATUS
 Patient from socio economic status SES V constituted 76% 
SES IV 16% and SES III 8%. Preterm labour is common in low 
socioeconomic and nutritional status. 
ANTENATAL CARE
Table :2
Booked 
/Unbooked
Nifedipine Group Control Group
No. % No. %
Booked 24 26.67% 16 18.39%
Unbooked 66 73.33% 71 81.61%
,,
Preterm labour was more common among unbooked patients 
while the booked patients who had atleast 3 visits were educated 
about preterm labour and its complications. Regular antenatal care 
was received by 26.67% in Nifedipine Group compared to 18.39% 
in control group .

OBSTETRIC HISTORY
Table :3
Gravida
Nifedipine Group Control Group
No. % No. %
Primi 60 66.67% 59 67.82%
II 29 32.22% 25 28.74%
III and 
above 1 1.11% 3 3.45%
66.67% and 67.82% of preterm labour was observed among primi gravida 
Nifedipine and control groups respectively.

PREDISPOSING FACTORS
Table: 4
S.No Factors
Nifedipine group Control Group
No. % No. %
1. Physical work 32 34.8% 29 32.9%
2. H/O Preterm labour 8 8.6% 7 7.9%
3 H/O Previous abortion 4 4.3% 6 6.8%
34.8% and 32.9% had history of excessive physical work, 8.6% and 
7.9% had previous preterm delivery, 4.3% and 6.8% had previous one or 
more abortions in Nifedipine and control groups respectively.

GESTATIONAL AGE
Table :5
GA 
(Weeks)
Nifedipine Group Control Group
No. % No. %
28-30 25 27.78% 26 29.89%
31-34 65 72.22% 61 70.11%
27.78% and 29.89% of preterm labour was observed in gestational 
age  between  28-30  weeks,  72.22%  and  70.11%  of  preterm  labour  was 
observed in gestational age between 31-34 weeks in Nifedipine and Control 
groups respectively.

CERVICAL DILATATION
Table : 6A
P/V
Dilation
Nifedipine Group Control Group
No. % No. %
1cm 41 45.55% 26 29.88%
2cm 38 42.22% 49 56.32%
3cm 11 12.22% 12 13.79%
            The cervix was 1cm dilated in 45.55% and 29.88%, 2cm dilated in 
42.22% and 56.32% and 3cm dilated in 12.22% and 13.79% in nifedipine 
and control groups respectively.

CERVICAL EFFACEMENT
Table : 6B
P/V
Effacement
Nifedipine Group Control Group
No. % No. %
25% 25 27.78% 15 17.24%
50% 49 54.44% 56 64.37%
75% 16 17.78% 16 18.39%
                The cervix  was 25% effaced in 27.78% and 17.24% of cases ,
50% effaced in 54.44% and 64.37% of cases and 75% effaced in 17.78% 
and 18.39% of cases  in nifedipine and control group respectively.

SUCCESS OF TOCOLYSIS
Table :7
Operation 
S/F
Nifedipine Group Control Group
No. % No. %
S 75 83.33% 52 59.77%
F 15 16.67% 35 40.23%
The  success  in  Nifedipine  and  Controls  are  83.33%  and  59.77% 
respectively. By test of proportion, the ‘p’ value was found to be .000 which 
is statistically significant. 

DOSAGE REQUIRED TO STOP CONTRACTIONS
Table : 8
S.No Dose of Nifedipine No. %
1 10mg 10 13.33%
2 20mg 39 52%
3 30mg 26 34.66%
20 mg of Nifedipine was required to suppress contractions in 52%, 
10mg in 13.33% and 30mg in 34.66% of patients in that group. 

RESPONSE ACCORDING TO GESTATIONAL AGE
Table: 9
GA 
(weeks)
Nifedipine Control
Success Failure Success Failure
No. % No. % No. % No. %
28-30 11 14.66% 14 93.33% 4 7.69% 22 62.86%
31-34 64 85.33% 1 6.67% 48 92.30% 13 37.14%
The prolongation of pregnancy more than 48 hours is  92.30% and 
85.33% in 31-34 weeks gestational age group, 7.69% and 14.66% in 28-30 
weeks gestational age group in control and nifedipine group respectively. P 
value is .757. 

DURATION OF PROLONGATION
Table :10
Prolongation beyond 1 week was observed in 15.52% in Nifedipine 
group 4.5% in control group.  Mean duration of prolongation in Nifedipine 
group was found to be 3.78 days. 
Prolongation 
period
Nifedipine Control
No. Percentage No. Percentage
<48hrs 15 16.66% 33 37.93%
48-72hrs 26 28.88% 21 24.13%
72hrs-1week 30 33.33% 29 33.33%
1week-2week 16 12.22% 3 3.4%
> 2week 3 3.3% 1 1.1%

MODE OF DELIVERY
Table :11
Mode of 
Delivery
Nifedipine Control
Success Failure Success Failure
No. % No. % No. % No. %
LSCS 2 1.92% 0 - 1 2.67% 0 -
Vaginal 73 98.08% 15 100% 51 97.33% 35 100%
98.08% and 97.83 % of cases delivered vaginally in Nifedipine and 
control success groups respectively. The p value (0.884) was insignificant. 
      2  cases  of  Nifedipine  group  underwent  LSCS  (Lower  Segment 
Caesarean Section) for PROM (Premature Rupture of Membranes) with no 
response to oxytocin. 
One case  in  control  group underwent  LSCS for  failed  response  to 
oxytocin.

RESPONSE ACCORDING TO CERVICAL EFFACEMENT
Table:12
          Among the patients who delivered successfully in the nifedipine and 
the control groups cervix was 25% effaced in 32% and 25% and was 50% 
effaced in 63% and 73.07%  respectively. P value 0.233. 
P/V 
Effacement
Nifedipine Control
Success Failure Success Failure
No. % No. % No. % No. %
25% 24 32% 1 6.67% 13 25% 2 5.71%
50% 47 63% 2 13.33% 38 73% 18 51.43%
75% 4 5% 12 80% 1 2% 15 42.86%


RESPONSE ACCORDING TO CERVICAL DILATATION
Table :13
P/V 
Dilatation
Nifedipine Control
Success Failure Success Failure
No. % No. % No. % No. %
1cm 39 52.00% 2 13.33% 23 44.23% 3 8.57%
2cm 36 48.00% 2 13.33% 28 53.85% 21 60.00%
3cm 0 0.00% 11 73.33% 1 1.92% 11 31.43%
The  patients  who  delivered  after  48  hours  in  the  nifedipine  and 
control groups had a cervical dilatation of 2cm in 48% and 53.85% and 1cm 
dilalation in 52% and 44.23 % respectively . P value is 0.138.
RESPONSE ACCORDING TO CERVICAL 
DILATATION 
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MATERNAL MORBIDITY 
Table :14
There was no maternal mortality. No case of postpartum hemorrhage 
in those who delivered within 48 hours.  
Sl.No Side effects Number
1 Tachycardia 12
2 Facial flushing 6
3 Headache 19
4 Hypotension 10
5 Nausea & Vomiting 4
FETAL AND NEONATAL EFFECTS
 Fetal tachycardia was observed in 3 cases in Nifedipine group. 
NEONATAL MORBIDITY
Table :15
Mode of 
Delivery
Nifedipine Control
Success Failure Success Failure
Birth 
asphyxia
- 1 2 2
RDS 1 3 3 6
Septicaemia - 2 1 4
IVH 1 1 1 2
Congenital 
anomalies
- - - 1
Better  neonatal  outcome  as  to  the  decrease  in  the  presence  of 
Respiratory Distress Syndrome (RDS) and other complications in neonates 
is more in Nifedipine success group. 
                                      NEONATAL MORTALITY
Table :16
S.No
Neonatal 
Mortality
Nifedipine (90) Control (87)
Success Failure Success Failure
1 Vaginal 2 (2.6%) 4(26.3%) 4(7.6%) 10(28.57%)
2.
Caesarean 
section
- - - -
The neonatal mortality was observed in 26.3% and 28.57% of failure 
cases delivered vaginally with Nifedipine and control groups respectively. 
No neonatal mortality was observed in caesarean group.
APGAR SCORE
Table: 17
S.No 5’ Apgar
Nifedipine Control
S F S F
No. % No. % No. % No. %
1 ≤5 2 2.67% 11 73.33% 12 23.08% 23 65.7%
2 6-7 18 24% 2 13.33% 9 17.31% 9 25.7%
3 >7 55 73.33% 2 13.33% 31 59.62% 3 8.57%
73.33 % and 59.62% who delivered successfully after 48 hours had 
Apgar of >7 in nifedipine and control groups respectively, the p value was 
significant 0.000.

WEIGHT OF BABY AT BIRTH
Table : 18
Birth 
weight 
(kg)
Nifedipine Control
S F S F
No. % No. % No. % No. %
<2 10 13.33% 14 93.33% 21 40.38% 26 74.29%
2-2.5 62 82.67% 1 6.67% 30 57.69% 9 25.71%
>2.5 3 4.00% 0 - 1 1.92% 0 -
            Among the success cases 82.67% in Nifedipine groups had birth 
weight  of  2-2.5kg compared  to  57.69% in control  success  group.  4% in 
nifedipine success group had birth weight of >2.5kg compared to 1.92% in 
control success groups. P value is .001 which is significant.

INCIDENCE OF RESPIRATORY DISTRESS SYNDROME
Table :19
RDS
Nifedipine Control
Success Failure Success Failure
No. % No. % No. % No. %
Present 1 1.35% 3 20% 3 5.7% 6 17.14%
Absent 74 98.66% 12 80% 49 94.22% 29 82.58%
The incidence of RDS is 1.35% in nifedipine success group and 5.7% 
in control success group (P value is 0.046).

DISCUSSION
DISCUSSION
              In our study the range of gestational age was 28 to 34 weeks.In 
other studies it  was 24 to 32 weeks (Nikolov et al)  and 26 to 34 weeks 
(Bekkari  et  al).  In Cochrane metaanalysis  by King JF et  al  in  2003,  the 
inclusion range of gestational age was from 20 to 26 weeks upto a maximum 
of 33.5 to 36 weeks.The trials in the metaanalysis excluded women with 
cervical dilation more than 4cm, while in our study the limit was 3cm.
         In our study the dosage of Nifedipine used is 30mg of loading dose 
given  as  10  mg  tablets  every  20  minutes  followed  3  hours  later  by  a 
maintenance dose of 10 mg of oral nifedipine 6 hourly for 3days. Similar to 
this a loading dose of oral nifedipine 3×10mg was used by Bekkari et al .A 
loading dose 4×10 mg of oral nifedipine was used by Nikolov et al in their 
study.
In Cochrane metaanalysis in 2003,the maximum dose used was 40 mg 
of  oral  Nifedipine  in  the  first  hour  followed  by  20mg  of  slow  release 
Nifedipine at t=90 minutes(Papatsonis et al).
Most  of  the  trials   in  the  Cochrane  metaanalysis  2003  measured 
outcome primarily by delay in delivery for more than 48 hours as in our 
study.9 out of 13 trials in this review reported a favourable outcome.Bekkari 
et al and Nikolov et al reported a success  of  84%  and 86.4% respectively, 
while in our study it was 83.33%.
Mean duration of prolongation of pregnancy in the Nifedipine group 
in  the  Cochrane  metaanalysis  was  3.83days  while  in  our  study  it  was 
3.78days.
 The most common side effects in the trials in Cochrane metaanalysis 
were hypotension and headache similar  to our study.Similar  to our study 
there  was no maternal  mortality  in any of  those trials  .No maternal  side 
effects  and  good  patient  tolerance  were  reported  by  Nikolov  et  al  and 
Bekkari et al respectively in their studies.
Similar  to  our  study  there  was  a  reduction  in  respiratory  distress 
syndrome  and  improved  Apgar  scores  at  5minutes  in  Cochrane  meta-
analysis 2003.
SUMMARY
SUMMARY
In the study with Nifedipine n-90 control n=87 it was observed that. 
1) Preterm labour was common in primigravida in the age group 20- 29 
years, belonging to lower socioeconomic status and who did not receive 
appropriate antenatal care. 
2) There were 71% of cases between 31& 34 weeks. 
3) Previous preterm delivery was found  in 8.3% ,previous abortions was 
found in 5.5% and physical stress like manual work travelling was found 
in 33.8% of the patients. 
4) The  success  of  Nifedipine  as  indicated  by  prolongation  of  pregnancy 
beyond  48  hours  was  observed  in  83.33%  of  cases  compared  with 
59.77% in controls. P value was significant(0.000)
5) Nifedipine dose 20mg was required in 52% of paitents, 30mg in 34.66% 
      of patients and 10mg in 13.33% of patients to stop contractions.
6) The prolongation of pregnancy more than 48 hours was found to be more 
       in 31-34 weeks of gestational age  in nifedipine and control groups.
 
. 
7) The cervix was  1cm dilated  in  45.55% and 29.88% ,  2cm dilated  in 
42.22%  and  56.32%  and  3cm  dilated  in  12.22%  and  13.79%   in 
nifedipine and control groups respectively.
8) The patients who delivered after 48 hours in the nifedipine and control 
groups had a cervical dilatation of 2cm in 48% and 53.85% and 1cm 
dilalation in 52% and 44.23 % respectively. P value is 0.138.
9)  The  cervix  was  25% effaced  in  27.78% and  17.24% of  cases  ,50% 
effaced in 54.44% and 64.37% of cases and75% effaced in 17.78% and 
18.39% of cases  in nifedipine and control group respectively
10) Among the patients who delivered successfully cervix was 25% effaced in 
32% and 25% and was 50% effaced in 63% and 73% of Nifedipine and 
control groups respectively 
11)Headache  and  maternal  tachycardia  were  the  commonest  side  effects 
observed.
12)The was no maternal mortality
13)Fetal mortality was due to complications of prematurity. Fetal tachycardia 
was observed in 3 cases.
14)The  percentage  of  cases  delivered  vaginally  in  Nifedipine  and  control 
success group were 79.3% and 98% respectively.
15)73.33  %  and  59.62%  of  neonates  of  patients  who  were  delivered 
successfully  after  48  hours  had  Apgar  of  >7 in  nifedipine  and  control 
groups respectively, the p value was significant 0.000. 
16)Among the success cases 82.67% in Nifedipine groups had birth weight of 
2-2.5kg compared to 57.69% in control success group. 4% in nifedipine 
success group had birth weight of >2.5kg compared to 1.92% in control 
success groups. P value is .001 which is significant.
17)The incidence of RDS is 1.35% in nifedipine success group and 20% in 
nifedipine failure group compared to 5.7% in control success group and 
14.3% in control failure group (P 0.046).Better neonatal outcome as to the 
decrease in the presence of RDS and other complications in neonates is 
more in nifedipine success group.
CONCLUSION
CONCLUSION
             Labour inhibiting drugs may not treat the cause of preterm 
labour but they only treat the symptoms, that is contractions. 
As these agents make the uterus refractory to contractile stimuli for a 
short time so that the perinatal outcome is improved. In this clinical study 
idiopathic spontaneous preterm labour whose onset was at 28 to 34 weeks 
has  responded  well  to  tocolytic  therapy  by  oral  nifedipine  and  neonatal 
outcome improved and no maternal mortality was observed. The maternal 
side  effects  were  reversed  on discontinuation  of  the  drug.  The  drug has 
provided the fetus of its valuable opportunity of being inside the mothers 
womb for a period enough to make the lungs mature by administration of 
exogenous steroids. 
      However  decrease  in  the  incidence  of  preterm  labour  lies  in 
identification  of  high  risk  patients,  improving  the  socio-  economic 
standards, better antenatal care, education and early detection of the onset of 
labour. 
          In developing countries neonatal intensive care are usually found in 
tertiary referral hospitals but not all such units have the required treatment 
capabilities. The statistically significant benefits of nifedipine in suppressing 
the uterine contractions for in utero transfer,in reducing neonatal respiratory 
distress syndrome along with its reduced maternal side effects, and its low 
cost  makes  it  to  be considered as  the first  line  tocolytic  agents  in  these 
countries.
PROFORMA
PROFORMA
Name Age 
IP.No Unit 
Gravida 
Para Last Menstrual Period (LMP)
Live Expected  Date  of  Delivery 
(EDD) 
Abortion Corrected EDD (C.EDD)
SES Menstrual cycle 
Occupation Height
Residence Weight 
Booked /Unbooked (UB)
Immunized / Not
DOA (Date of Admission) 
Duration of Hospital stay 
DOD (Date of Discharge) 
Period of gestation 
Present complaints
Lower abdominal pain 
Dull low backache
Vaginal discharge
Fluid leaking per vaginum
Fever 
UTI   (Urinary Tract Infection) 
URI (Upper Respiratory Tract Infection) 
Bleeding 
Obstetric history 
I. Trimester 
Hyperemesis
Exanthematous fever 
Bleeding 
Radiation exposure 
Medication 
Pain abdomen 
II. Trimester 
Date of Quickening 
Bleeding per vaginum 
History of (H/O) PIH
H/O GDM (Gestational Diabetes Mellitus)
III. Trimester 
Bleeding per vaginum
UTI
Cervico vaginal infection 
Coitus
Diabetes
Hypertension 
Fever
Trauma
Past obstetric history 
Previous child birth 
H/O abortion 
H/O Preterm labour 
H/O Babies with congenital anamolies
Past Medical History 
Tuberculosis
Bronchial Asthma 
STD  (Sexually Transmitted Diseases) 
Jaundice 
Renal disease
Heart disease 
Diabetes mellitus 
Epilepsy 
General examination 
Temperature (T) Pallor Pedal 
edema
PR BP RR               RS           CVS
Obstetric examination 
Per Abdomen ;-   
Fundal height 
Symphysio fundal height
Contractions 
Presentation 
Position 
Liquor 
FHR  (Fetal Heart Rate) 
Expected Fetal Weight at admission
Weight after birth 
Per Vaginal Examination (P/V)
          Cervix
Membranes
Pelvis 
Investigations 
Urine analysis
Urine culture sensitivity
Complete Blood Count
Blood urea, 
         Sugar 
S. Creatinine 
S. Electrolytes 
ECG
USG Abdomen
Nifedipine
Time Dose Contractions T PR BP RR FHR P/V
Side effects 
Period of tocolysis
Mode of delivery 
Fetal Outcome 
Birth weight 
Apgar
Neonatal complications
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